Atai Beckley Inc Stock Price, News & Analysis

AtaiBeckley (NASDAQ: ATAI) completed the redomiciliation of its parent from a Netherlands company to a Delaware corporation, effective after market close on Dec 30, 2025. All issued ordinary shares were exchanged on a one-for-one basis for newly issued common stock of AtaiBeckley Inc.

The redomiciliation was approved by approximately 99% of votes cast at the extraordinary general meeting on Nov 4, 2025. The company said it expects cost savings, simplified corporate structure, alignment with its U.S. listing and shareholder base, streamlined reporting and reduced administrative burden. Common stock will continue trading on NASDAQ under the symbol ATAI. For further details, see the company filings with the SEC.

AtaiBeckley (NASDAQ: ATAI) said its common stock was added to the NASDAQ Biotechnology Index (NBI), effective prior to market open on Dec 22, 2025. The company cited progress in 2025 including approximately $300 million of capital raised, advancement of multiple clinical programs toward late‑stage development, a strategic combination between atai Life Sciences and Beckley Psytech, and an expected U.S. corporate domiciliation around year‑end.

The NBI tracks Nasdaq‑listed biopharma securities meeting market‑cap, trading volume, and seasoning criteria and is selected annually in December; inclusion can increase visibility among index funds and institutional investors.

AtaiBeckley (NASDAQ: ATAI) announced a U.S. patent grant (No. 12,492,178) for EMP-01 (oral R‑MDMA), which the company says provides exclusivity through 2043. The patent covers a highly crystalline HCl salt form with high aqueous solubility and low hygroscopicity, attributes cited as beneficial for formulation, manufacture, and storage.

The company states this strengthens its intellectual property estate and supports advancement of EMP-01 toward clinical development; topline data from an exploratory Phase 2a study in adults with social anxiety disorder is expected in Q1 2026.

Enhanced (ATAI) announced a major leadership reshuffle on Nov 19, 2025, naming Co‑founder Maximilian Martin as CEO and Co‑founder Christian Angermayer as Executive Chairman while Jim Murren joins the board.

Enhanced also appointed Sid Banthiya as CFO, promoted Alex Lopez to Chief Brand Officer and Rick Adams to Chief Sporting Officer, and named Chris Jones Chief Communications Officer. Background highlights include Martin's prior company sale in a €400 million transaction and Angermayer's family office overseeing $7 billion AUM.

Atai Beckley (NASDAQ: ATAI) will participate in the Jefferies Global Healthcare Conference in London.

Who: Srinivas Rao, M.D., Ph.D., CEO, and Kevin Craig, M.D., CMO. Format: Fireside chat and one-on-one investor meetings. When: Fireside chat on Thursday, November 20, 2025 at 11:30 A.M. GMT / 6:30 A.M. ET. Webcast: A live webcast is provided and an archived replay will be available on the company Investors Events page for up to 90 days.

AtaiBeckley (NASDAQ: ATAI) reported Q3 2025 results and corporate updates highlighting clinical and financing milestones. Key items include FDA Breakthrough Therapy designation for BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, positive Phase 2a and Phase 2b OLE topline data for BPL-003, and an End-of-Phase 2 meeting with FDA with Phase 3 guidance expected in Q1 2026 and anticipated Phase 3 start in Q2 2026. The company completed enrollment in the Phase 2a EMP-01 study for social anxiety disorder and expanded VLS-01 Phase 2 sites internationally. AtaiBeckley closed an approximate $150 million public offering, reported cash, cash equivalents and short-term securities of $114.6 million as of Sept 30, 2025, and expects liquidity to fund operations into 2029. The company also secured a NIDA grant worth up to $11.4 million for novel 5-HT2A/2C programs.

AtaiBeckley (NASDAQ: ATAI) reported positive topline results from the Phase 2b open-label extension (OLE) of BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression on Nov 10, 2025.

Key findings: a 12 mg re-dose eight weeks after an initial dose produced additional rapid antidepressant effects sustained up to eight weeks; pooled active-core patients (n=60) showed a mean MADRS reduction of 19.0 points and 63% responder / 48% remission at Day 57 (Week 16). Safety was consistent with prior studies; most adverse events were mild/moderate and transient; one drug-related serious adverse event resolved.

The company scheduled an End-of-Phase 2 meeting with the FDA and expects Phase 3 guidance in Q1 2026 with potential initiation in Q2 2026.

AtaiBeckley (NASDAQ: ATAI) announced completion of the strategic combination between atai Life Sciences and Beckley Psytech on Nov 5, 2025, creating a clinical‑stage company focused on psychedelic‑based neuroplastogens.

Key facts: BPL-003 is Phase 3‑ready with FDA Breakthrough Therapy designation and Phase 3 initiation expected Q2 2026; VLS-01 topline data expected H2 2026; EMP-01 topline data expected Q1 2026. Management and board roles were established and the company expects cash and liquid assets to fund operations into 2029. The deal issues ~105 million new shares (~28% of combined company) and a Delaware redomiciliation is expected around year‑end.

atai Life Sciences (NASDAQ: ATAI) closed a public offering on October 20, 2025, issuing 27,283,750 common shares (including full exercise of a 3,558,750-share underwriter option) at $5.48 per share.

The offering generated approximately $149.5 million in aggregate gross proceeds before fees. atai said it will use net proceeds together with existing cash and liquid assets to fund its pipeline, including the planned Phase 3 program for BPL-003 through first top-line readout, completion of the Phase 2 VLS-01 trial and the Phase 2a EMP-01 study, plus working capital. Based on this use, atai estimates cash will fund operations into 2029.